Literature DB >> 31724172

TBET-expressing Th1 CD4+ T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in Eµ-TCL1 mice.

Philipp M Roessner1, Bola S Hanna1, Selcen Öztürk1, Ralph Schulz1,2, Laura Llaó Cid1,2, Haniyeh Yazdanparast1, Annika Scheffold3, Dolors Colomer4, Stephan Stilgenbauer3, Peter Lichter1, Martina Seiffert1.   

Abstract

Chronic lymphocytic leukaemia (CLL) is associated with alterations in T cell number, subset distribution and function. Among these changes, an increase in CD4+ T cells was reported. CD4+ T cells are a heterogeneous population and distinct subsets have been described to exert pro- and anti-tumour functions. In CLL, controversial reports describing the dominance of IFNγ-expressing Th1 T cells or of IL-4-producing Th2 T cells exist. Our study shows that blood of CLL patients is enriched in Th1 T cells producing high amounts of IFNγ. Moreover, we observed that their frequency remains relatively stable in CLL patients over a time course of five years. Furthermore, we provide evidence for an accumulation of Th1 T cells in the Eµ-TCL1 mouse model of CLL. As TBET (encoded by Tbx21) is a crucial transcription factor for Th1 polarization, we generated Tbx21-/- bone marrow chimaeric mice which showed a lower number of IFNγ-producing Th1 T cells, and used them for adoptive transfer of Eµ-TCL1 leukaemia. Disease development in these mice was, however, comparable to that in wild-type controls, excluding a major role for TBET-expressing Th1 cells in Eµ-TCL1 leukaemia. Collectively, our data highlight that Th1 T cells accumulate in CLL but reducing their number has no impact on disease development.
© 2019 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  CD4+ T cells; CLL; IFNγ; TBET; Th1

Year:  2019        PMID: 31724172     DOI: 10.1111/bjh.16316

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

Review 1.  Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.

Authors:  Valentina Griggio; Francesca Perutelli; Chiara Salvetti; Elia Boccellato; Mario Boccadoro; Candida Vitale; Marta Coscia
Journal:  Front Immunol       Date:  2020-11-18       Impact factor: 7.561

2.  EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia.

Authors:  Philipp M Roessner; Laura Llaó Cid; Ekaterina Lupar; Ana Izcue; Martina Seiffert; Tobias Roider; Marie Bordas; Christoph Schifflers; Lavinia Arseni; Ann-Christin Gaupel; Fabian Kilpert; Marit Krötschel; Sebastian J Arnold; Leopold Sellner; Dolors Colomer; Stephan Stilgenbauer; Sascha Dietrich; Peter Lichter
Journal:  Leukemia       Date:  2021-02-01       Impact factor: 11.528

3.  CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.

Authors:  Matteo Grioni; Arianna Brevi; Elena Cattaneo; Alessandra Rovida; Jessica Bordini; Maria Teresa Sabrina Bertilaccio; Maurilio Ponzoni; Giulia Casorati; Paolo Dellabona; Paolo Ghia; Matteo Bellone; Arianna Calcinotto
Journal:  Blood Adv       Date:  2021-07-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.